Safety of Alfaxan® in dogs and cats

Alfaxan® Anaesthetic Injection
### Safety of Alfaxan® in dogs and cats

**Alfaxan® Injectable Anaesthetic** is registered for the induction and/or maintenance of anaesthesia in dogs and cats. It can be used for maintenance of anaesthesia by either Constant Rate Infusion (CRI) or repeated bolus administration.

It is marketed in many countries around the world including Australia, New Zealand, UK, Ireland, France, Germany, Spain, Canada and the Netherlands. In Australia where it was first registered, it has been marketed for over 10 years. A survey of anaesthetic use throughout Australia conducted in 2011 showed that Alfaxan® is now used in over 50% of all inductions in dogs and over 75% of all inductions in cats.[1]

For veterinarians who are yet to use Alfaxan®, the first question is, “How safe is the product?” Whilst authorities frown upon use of the word “safe” when speaking of any drug - especially anaesthetic agents – extensive trial work has been done examining the safety of Alfaxan® in both dogs and cats and it is presented below.

These data, along with the product’s track record since its introduction over ten years ago, should give veterinarians a high degree of comfort when considering the addition of the product to their anaesthetic protocols.

### Over-dosage studies

**A. Single, acute over-dosage**

Acute tolerance to over-dosage with Alfaxan® has been demonstrated at up to 10 times the recommended dose of 2 mg/kg in dogs and up to 5 times the recommended dose of 5 mg/kg in cats.[2, 3]

**B. Repeated over-dosage**

Repeated overdosing of Alfaxan® at 5 times the recommended rate in dogs and 5 times the recommended rate in cats, at 48 hour intervals on 3 occasions over 7 days, caused no adverse effects.[4, 5]

The tolerance to such high levels of over-dosage in dogs and cats – either as a single dose, or in a schedule of repeated over-dosage - demonstrates that, used as recommended, Alfaxan® is a stress-free anaesthetic agent.

### Tissue tolerance

Alfaxan® does not cause tissue irritation after perivascular, subcutaneous or intramuscular injection.[6]

This is important when a product is new to the clinic and staff may be inexperienced in its use. The lack of tissue reaction is due to the fact that Alfaxan® is a clear, aqueous, pH neutral, iso-osmolar solution. In fact the product is registered for intramuscular (IM) injection in the cat, proof of its lack of irritancy.

### Age tolerance

Alfaxan® can be used to supply anaesthesia in juvenile patients - puppies and kittens from 6 weeks of age.[7, 8]

Whilst surgery on very young animals may be infrequent, it is useful for veterinarians and practice managers to
know that with Alfaxan® they have an anaesthetic agent that will cover this age cohort – there is no need to have specialised products.

**Sighthounds**

Alfaxan® has been proven to be a reliable and effective anaesthetic induction agent in sighthounds.[9]

Greyhounds and other breeds in this group have shown differing responses to sedation and anaesthesia when compared with other dog breeds. Use of Alfaxan® in sighthounds - as the paper cited above demonstrates – is incident-free and similar to that seen in other breeds. Premedication agents however, have the capacity to significantly increase the duration of anaesthesia seen in these animals.

**Caesarean section**

Alfaxan® has been proven to be reliable and effective as an anaesthetic induction agent in canine Caesarean section.[10]

In a controlled GCP multi-site investigation, involving four veterinary hospitals, 48 bitches receiving Alfaxan® for anaesthetic induction were compared to 26 bitches receiving propofol for anaesthetic induction prior to performance of Caesarean sections. Analysis of anaesthetic induction scores, puppy survival and puppy vigour data showed Alfaxan® to be equal to, or better than propofol.

Thus Alfaxan® can be used with confidence in Caesarean sections.

**Cardio-vascular and respiratory function**

Alfaxan® has minimal effect on cardiovascular function.[2, 3]

When Alfaxan® is used for induction, blood pressure is well maintained and this provides acceptable tissue perfusion - important in sustaining normal tissue/organ function.

Alfaxan®, when administered as recommended, causes minimal dose-dependent respiratory depression.[11, 12]

When Alfaxan® is administered for induction, in accordance with the label, patients tend to breathe spontaneously, which allows smooth transition to gaseous maintenance.

**Compatibility**

Alfaxan® has been proven compatible with the major groups of premedication agents.[7-9, 11, 12, 14-25] This means, in practical terms, the introduction of Alfaxan® to the clinic does not alter the premedication protocols which are in place.

In fact it is strongly recommended that anxiolytics, premedicants and pain modulation agents are used as part of every procedure to ensure optimal induction, transition, anaesthesia and recovery.

**Muscle relaxation**

Alfaxan® provides good muscle relaxation[2, 3], therefore there is no need for adjunctive muscle relaxants.

**General**

Alfaxan® is based on alfaxalone, a neuroactive steroid, very similar in structure to progesterone (though it does not have its pharmacological activity). Alfaxalone acts on the neuronal cell membrane chloride ion transport by binding to the GABA<sub>A</sub> cell surface receptors. Due to its similarity to endogenous steroids, which have well-developed metabolic pathways, alfaxalone is eliminated rapidly from the body via the bile and urine. It is cleared within a few hours.[13]

Based on the above studies and a wealth of field experience, veterinarians can incorporate Alfaxan® into their anaesthetic procedures for dogs and cats with a high level of confidence.
References


4. Whittem, T. and Pasloske, P., RD9604.03 – H005. Eight day target animal safety study of intravenous Alfaxan® CD RTU in dogs administered every other day. 2004, Jurox Pty. Ltd.

5. Pasloske, K. and Whittem, T., JX9604.07-H004. A target animal safety study in cats after administration of Alfaxan® CD RTU as single, repeated injections on days 0, 2 and 5 at doses of 5, 15 or 25 mg/kg. 2004, On file at Jurox Pty Ltd.


For more information contact:

Jurox Pty Limited
85 Gardiner Street
Rutherford
NSW, 2320
Australia
Enquiries +61 (0)2 49 318 200
jenq@jurox.com.au

Jurox New Zealand Limited
8 Kordel Place
East Tamaki
Auckland, 2013
New Zealand
Enquiries 0800 587 696
admin@jurox.co.nz

® Registered Trademark of Jurox Pty Limited